LOS ANGELES, March 13, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer will be presenting at the Barclays Global Healthcare Conference on Thursday, March 16, 2023 at 9:30 a.m. Eastern Time (6:30 a.m. Pacific Time).
There will be simultaneous and archived webcasts available at https://event.webcasts.com/event_security_fail.html
and www.radnet.com under the “About RadNet'' menu section and “News and Press Releases'' sub-menu of the website.
Details for RadNet's Presentation: | |||
Date: | Thursday, March 16, 2023 | ||
Time: | 9:30 a.m. Eastern Time / 6:30 a.m. Pacific Time | ||
Location: | Loews Miami Beach Hotel | ||
URL: https://event.webcasts.com/event_security_fail.html |
About RadNet, Inc.
RadNet, Inc., is the leading national provider of freestanding, fixed-site diagnostic imaging services and related information technology solutions (including artificial intelligence) in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 357 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey and New York. Together with affiliated radiologists, inclusive of full-time and per diem employees and technologists, RadNet has a total of over 9,000 employees. For more information, visit http://www.radnet.com.
Contact:
RadNet, Inc.
Mark Stolper, Executive Vice President and Chief Financial Officer
310-445-2928
Last Trade: | US$73.81 |
Daily Change: | 2.09 2.91 |
Daily Volume: | 522,027 |
Market Cap: | US$5.680B |
September 26, 2025 September 08, 2025 August 07, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load